Clinical effects of carvedilol and trimetazidine for the treatmentof alcoholic myocardiopathy
- Authors:
- Hui Li
- Fu-Yuan Liu
- Xiao-Lan Li
- Xiao-Mei Li
- Lei Zhu
View Affiliations
Affiliations: Department of Cardiovascularology, Xiangyang Hospital Affiliated to Hubei University of Medicine, Xiangyang, Hubei 441001, P.R. China
- Published online on: May 19, 2016 https://doi.org/10.3892/etm.2016.3363
-
Pages:
979-982
-
Copyright: © Li
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
The aim of the study was to compare the clinical effects of carvedilol and trimetazidine for the treatment of alcoholic cardiomyopathy. A total of 60 patients diagnosed with alcoholic cardiomyopathy were enrolled in the study. The patients were randomly divided into the carvedilol (n=20), trimetazidine (n=20) and control (n=20) groups. The patients in the control, carvedilol and trimetazidine groups were treated with conventional drugs, conventional drugs + carvedil and conventional drugs + trimetazidine respectively, for 12 weeks. The patients were compared for their heart functions [left ventricular ejection fraction (LVEF), C-reactive protein (CRP) and 6 min walking], heart rate, blood pressure and heart enlargement (cardiothoracic proportion and left ventricular diameter) before and after treatment. The parameters studied for heart functions, heart rate, blood pressure, heart enlargement, clinical effects before and after treatment were statistically insignificant (p>0.05). After treatment, the carvedilol and trimetazidine groups showed higher LVEF and CRP, longer walking distance in 6 min, as well as lower heart rate and blood pressure (both systolic and diastolic) compared to the control group. Similarly, the cardiothoracic proportion and left ventricular internal diameter for the carvedilol and trimetazidine groups was lower than those of the control group, with better clinical effects (p<0.05). In conclusion, the curative effects of the carvedilol and trimetazidine groups of alcoholic myocardiopathy similar. Both are safe agents that may improve the cardiac function and heart expansion of patients.
View References
|
1
|
Kollar J: [Clinical picture of alcoholic
myocardiopathy. Review]. Vnitr Lek. 18:172–181. 1972.PubMed/NCBI
|
|
2
|
Mamas MA, Deaton C, Rutter MK, Yuille M,
Williams SG, Ray SG, New J, Gibson JM and Neyses L: Impaired
glucose tolerance and insulin resistance in heart failure:
underrecognized and undertreated? J Card Fail. 16:761–768. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jun H and Bo Y: New progress in the
pathogenesis of alcoholic cardiomyopathy. Chin J Evid-Based
Cardiovasc Med. 6:236–237. 2014.(In Chinese).
|
|
4
|
Estruch RR: [Alcoholic myocardiopathy].
Rev Clin Esp. 201:137–139. 2001.PubMed/NCBI
|
|
5
|
Sugihara K, Fujimoto S, Motomiya Y,
Hashimoto T, Nakamura S and Dohi K: Usefulness of long axis M-mode
echocardiographic measurements for optimum dialysis in patients on
maintenance hemodialysis: comparison with changes in plasma levels
of atrial natriuretic peptide and brain natriuretic peptide. Clin
Nephrol. 56:140–149. 2001.PubMed/NCBI
|
|
6
|
Gvozdjak A, Bada V, Kruty F, Niderland TR
and Gvozdjak J: [Mechanism of the development of cardiac
insufficiency in alcoholic myocardiopathy]. Kardiologiia.
16:136–137. 1976.PubMed/NCBI
|
|
7
|
Mahfoudh-Boussaid A, Hadj Ayed Tka K,
Zaouali MA, Roselló-Catafau J and Ben Abdennebi H: Effects of
trimetazidine on the Akt/eNOS signaling pathway and oxidative
stress in an in vivo rat model of renal ischemia-reperfusion. Ren
Fail. 36:1436–1442. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu H, Yang J and Ding J: Effects of
capsule on cardiac functions and expression of HMGB1 of patients
with dilated cardiomyopathy. Chin J Evid-Based Cardiovasc Med.
6:271–273. 2014.(In Chinese).
|
|
9
|
Schwarz F, Mall G, Zebe H, Schmitzer E,
Manthey J, Scheurlen H and Kübler W: Determinants of survival in
patients with congestive cardiomyopathy: quantitative morphologic
findings and left ventricular hemodynamics. Circulation.
70:923–928. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arranz CJ, Lopez JL, Moya MM and Martin
JT: [Reversibility of alcoholic myocardiopathy]. Med Clin (Barc).
93:316–317. 1989.PubMed/NCBI
|
|
11
|
Wang CM, Almsherqi ZA, McLachlan CS,
Matthews S, Ramachandran M, Tay SK and Deng Y: Acute starvation in
C57BL/6J mice increases myocardial UCP2 and UCP3 protein expression
levels and decreases mitochondrial bio-energetic function. Stress.
14:66–72. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Aubert A, Bernard C, Clauser P, Harpey C
and Vaudry H: [A cellular anti-ischemic agent, trimetazidine
prevents the deleterious effects of oxygen free-radicals on the
internal ear]. Ann Otolaryngol Chir Cervicofac. 107:28–35. 1990.(In
French). PubMed/NCBI
|
|
13
|
Duan M, Wang L, Cao X and Huang G: The
effect of coenzyme Q10 combined with trimetazidine for treatment of
elderly patients with alcoholic cardiomyopathy heart failure. Chin
J Gerontol. 32:4379–4381. 2012.
|
|
14
|
Dijkstra AF, Verdonk P and Lagro-Janssen
AL: Gender bias in medical textbooks: examples from coronary heart
disease, depression, alcohol abuse and pharmacology. Med Educ.
42:1021–1028. 2008. View Article : Google Scholar : PubMed/NCBI
|
